Among others, the human monoclonal antibody directed towards IL-1ß also reduced major cardiovascular events (MACE) in patients with CKD, thereby indicating a cardioprotective effect in RCS, but failed to reduce the number of renal events 13. This evidence concerns the gene IL1B and chronic kidney disease.